An­oth­er hic­cup for GW Phar­ma's seizure drug ri­val, as Zo­genix dis­clos­es FDA re­view de­lay

Zo­genix has had a trou­bling 2020 so far. Ear­li­er this month, its ex­per­i­men­tal seizure drug met the main goal in a piv­otal study in pa­tients with Lennox-Gas­taut Syn­drome, but the com­pa­ny saw its shares plum­met af­ter the mag­ni­tude of the ther­a­py’s ef­fect fell short of Wall Street ex­pec­ta­tions. On Thurs­day, the drug de­vel­op­er said that the FDA had ex­tend­ed the re­view of the drug in pa­tients with Dravet syn­drome by three months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER